Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 9/20 | 0.63 |
| ▸ | UMPS | P11172 | 4/20 | 0.62 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.53 |
| ▸ | P2RY6 | Q15077 | 6/20 | 0.52 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.51 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12143118 | 1.00 | P2RY2 (0.63) | P2RY2UMPSDNPH1P2RY6P2RY4 | |
| SCHEMBL12143540 | 1.00 | P2RY2 (0.63) | P2RY2UMPSDNPH1P2RY6P2RY4 | |
| SCHEMBL15196242 | 1.00 | P2RY2 (0.63) | P2RY2UMPSDNPH1P2RY6P2RY4 | |
| SCHEMBL15196259 | 1.00 | P2RY2 (0.63) | P2RY2UMPSDNPH1P2RY6P2RY4 | |
| SCHEMBL17363861 | 1.00 | P2RY2 (0.63) | P2RY2UMPSDNPH1P2RY6P2RY4 | |
| SCHEMBL15522444 | 1.00 | P2RY2 (0.63) | P2RY2UMPSDNPH1P2RY6P2RY4 | |
| SCHEMBL17363860 | 0.92 | P2RY2 (0.58) | P2RY2UMPSP2RY6P2RY4P2RY14 | |
| SCHEMBL12727821 | 0.87 | P2RY2 (0.61) | P2RY2UMPSDNPH1P2RY6P2RY4 | |
| SCHEMBL2130675 | 0.87 | P2RY2 (0.61) | P2RY2UMPSDNPH1P2RY6P2RY4 | |
| SCHEMBL12143538 | 0.86 | UMPS (0.65) | P2RY2UMPSDNPH1P2RY6P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9194802-B2 | Luminescent probes having a phenanthridinyl antenna, and methods of use | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2015-11-24 | — | — | US | claimed |
| US-20140080163-A1 | LUMINESCENT PROBES HAVING A PHENANTHRIDINYL ANTENNA, AND METHODS OF USE | NATIONAL SCIENCE FOUNDATION | 2014-03-20 | — | — | US | claimed |
| EP-1931691-B1 | ODCASE INHIBITORS FOR THE TREATMENT OF MALARIA | UNIV HEALTH NETWORK (CA) | 2013-08-21 | — | — | EP | claimed |
| US-8067391-B2 | ODCase inhibitors for the treatment of malaria | UNIVERSITY HEALTH NETWORK (CA) | 2011-11-29 | — | — | US | claimed |
| US-20100056468-A1 | Pyrimidine Derivatives As Anticancer Agents | UNIVERSITY HEALTH NETWORK (CA) | 2010-03-04 | — | — | US | claimed |
| US-20090221524-A1 | ODCASE INHIBITORS FOR THE TREATMENT OF MALARIA | UNIVERSITY HEALTH NETWORK (CA) | 2009-09-03 | — | — | US | claimed |
| WO-2008083465-A1 | PYRIMIDINE DERIVATIVES AS ANTICANCER AGENTS | UNIVERSITY HEALTH NETWORK (CA) | 2008-07-17 | — | — | WO | claimed |
| EP-3130597-B1 | OLIGONUCLEOTIDE HAVING A NON-NATURAL NUCLEOTIDE AT THE 5'-TERMINAL | KYOWA KIRIN CO LTD (JP) | 2021-11-10 | — | — | EP | disclosed |
| EP-2891717-B1 | OLIGONUCLEOTIDE | KYOWA KIRIN CO LTD (JP) | 2020-04-29 | — | — | EP | disclosed |
| US-10378011-B2 | Oligonucleotide | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2019-08-13 | — | — | US | disclosed |
| US-10378011-B2 | Oligonucleotide | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2019-08-13 | — | — | US | disclosed |
| US-10342819-B2 | Oligonucleotide having non-natural nucleotide at 5′-terminal thereof | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2019-07-09 | — | — | US | disclosed |
| US-10342819-B2 | Oligonucleotide having non-natural nucleotide at 5′-terminal thereof | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2019-07-09 | — | — | US | disclosed |
| EP-1931691-B1 | ODCASE INHIBITORS FOR THE TREATMENT OF MALARIA | UNIV HEALTH NETWORK (CA) | 2013-08-21 | — | — | EP | disclosed |
| US-8067391-B2 | ODCase inhibitors for the treatment of malaria | UNIVERSITY HEALTH NETWORK (CA) | 2011-11-29 | — | — | US | disclosed |
| US-20100056468-A1 | Pyrimidine Derivatives As Anticancer Agents | UNIVERSITY HEALTH NETWORK (CA) | 2010-03-04 | — | — | US | disclosed |
| US-20090221524-A1 | ODCASE INHIBITORS FOR THE TREATMENT OF MALARIA | UNIVERSITY HEALTH NETWORK (CA) | 2009-09-03 | — | — | US | disclosed |
| WO-2008083465-A1 | PYRIMIDINE DERIVATIVES AS ANTICANCER AGENTS | UNIVERSITY HEALTH NETWORK (CA) | 2008-07-17 | — | — | WO | disclosed |
| EP-1931691-A1 | ODCASE INHIBITORS FOR THE TREATMENT OF MALARIA | University Health Network (CA) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007038859-A1 | ODCASE INHIBITORS FOR THE TREATMENT OF MALARIA | UNIVERSITY HEALTH NETWORK (CA) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221524-A1 | ODCASE INHIBITORS FOR THE TREATMENT OF MALARIA | UMPS, UGDH, UPP1 | P2RY2 996/4885UMPS 1/4885DNPH1 222/4885 |
| US-10378011-B2 | Oligonucleotide | HNRNPA3, AGO2, RBM3 | P2RY2 4450/4885UMPS 2959/4885DNPH1 4323/4885 |
| US-20100056468-A1 | Pyrimidine Derivatives As Anticancer Agents | DPYD, TYMP, TYMS | P2RY2 1891/4885UMPS 17/4885DNPH1 2623/4885 |
| US-10342819-B2 | Oligonucleotide having non-natural nucleotide at 5′-terminal thereof | RNGTT, UPF1, NSUN3 | P2RY2 2497/4885UMPS 548/4885DNPH1 2051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.